Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Abstract

Neoadjuvant sintilimab was tolerable for patients with NSCLC, and 40.5% MPR rate is encouraging. The decrease of maximum standardized uptake values after sintilimab might predict pathologic response.